With a market cap of $23.5 billion, Quest Diagnostics Incorporated (DGX) is a leading healthcare company that provides advanced diagnostic testing and laboratory insights to improve patient care and health outcomes. Serving half of the physicians and hospitals in the United States and one in three adult Americans annually, the company empowers clinicians and consumers with smarter, simpler testing to help create a healthier world, one life at a time.
The Secaucus, New Jersey-based company is slated to announce its fiscal Q2 2026 results before the market opens on Thursday, Jul. 23. Ahead of the event, analysts expect DGX to report an adjusted EPS of $2.81, up 7.3% from $2.62 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarterly reports.
